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tissue microarray, the lower expression of PITX1 was found to be 
signiﬁcantly linked to higher tumor stages. Additionally, increased 
PITX1 expression was found in a NSCLC cell line H2228 and a SCLC 
cell line H526 after they were exposed to the differentiation modifying 
agent BrdU indicating the potential role of PITX1 in lung cancer dif-
ferentiation and carcinogenesis (Chen et al. 2007c).
LAGY/HOP, a novel tumor suppressor in lung cancer.
Previously, we ﬁrst isolated the full-length sequence of LAGY/HOP 
and observed that this gene was downregulated in a panel of lung can-
cer cell lines as well as in a majority of primary lung tumors (Chen et 
al. 2003). Recently, we constructed an expression vector containing the 
full-length cDNA of LAGY/HOP and transfected it into the lung cancer 
cell line H2170. Stable transfection led to an increased expression of 
LAGY/HOP. LAGY/HOP positive transfectants remarkably reduced 
the growth rate and the ability of anchorage-independent growth in 
soft agar, and moreover suppressed the tumor formation in nude mice. 
Transient transfection of Nkx2.1 into H2170 resulted in the overexpres-
sion of LAGY/HOP, and correspondingly, siRNA silencing of Nkx2.1 
reduced the expression of LAGY/HOP in lung cancer cells. Further-
more, increased expression of LAGY/HOP was observed in the BrdU 
modiﬁed differentiation cell model. Our data suggest that LAGY/HOP 
is a potential tumor suppressor possibly involved in lung cancer differ-
entiation, and functions downstream of Nkx2.1 (Chen et al. 2007d).
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Prognostic and predictive markers in lung cancer-emphasis on 
receptor tyrosine kinases egfr and met
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Genetic and proteomic proﬁling of lung cancer has given way to a 
number of molecularly targeted therapeutics. As new molecules are 
identiﬁed to be important in lung cancer, we will need to determine 
their role as prognosticators and ultimately as predictive markers. 
A prognostic marker helps determine the progression of lung cancer 
and ultimate outcome; whereas, a predictive marker represents how a 
patient may respond to a particular type of treatment. Studies of recep-
tor tyrosine kinases (RTKs), such as epidermal growth factor receptor 
(EGFR) and Met, have also lead to therapeutic target inhibition in solid 
tumors. In particular, overexpression of EGFR is a poor prognostica-
tor in a number of solid tumors, especially lung cancer. Using small 
molecule inhibitors (such as erlotinib) and antibody (such cetuximab) 
against EGFR, a number of predictive markers have been utilized. The 
predictive markers can include expression of EGFR, phosphorylated 
EGFR, and downstream targets such as Akt via immunohistochemistry 
(IHC). Predictive markers for EGFR therapies also include gene ampli-
ﬁcation (with FISH) and mutational analysis. In spite of a large number 
of studies on EGFR and EGFR inhibitors, there is no clear consensus 
on the use of predictive markers. Some important facts that are emerg-
ing: 1. Mutational status of EGFR is predictive of response; 2. FISH is 
predictive of survival; 3. K-ras mutation is a negative predictor; 4. Rash 
is prognostic but not necessarily predictive. Met is another RTK that 
is overexpressed in lung cancer, sometimes ampliﬁed, as well poten-
tially mutated. The mutations of Met rarely occur in the tyrosine kinase 
domain in lung cancer; however, a large number of mutations are in 
the semaphorin domain as well in the juxtamembrane (JM) domain. 
These mutations lead to gain of functions, and there appears to be a 
difference in mutations in various histologies as well in different ethnic 
backgrounds. We have identiﬁed that Met and its ligand, hepatocyte 
growth factor (HGF), are important prognosticators in lung cancer. 
There are several inhibitors agains Met/HGF that are already in clinical 
trials. It is to be determined with the various Met inhibitors if there are 
also predictive markers, and this will be discussed. Certainly, there are 
a large number of markers that are prognostic/predictive in lung cancer 
(such as the recently identiﬁed ERCC1 and RRM1; and a plethora of 
other gene/protein markers); however, rigorous prospective validation 
of biological and clinical markers of sensitivity needs to be performed.
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Lung cancer is the most serious cause of cancer mortality worldwide. 
The current clinical staging system can not accurately predict risk of 
patients. To develop an outcome prediction method for personalized 
therapy of lung cancer is the most important goal of cancer genomics.. 
To identify gene signature that can predict survival and metastasis in 
lung cancer patients, we examined the gene expressions in surgical 
specimens of 125 NSCLC patients using microarray and real-time RT-
PCR and correlated with survival of the patients. We used the risk score 
and decision-tree methods to develop a gene-expression predictive 
model to predict the clinical outcome of NSCLC. We have identiﬁed 
sixteen genes that correlated with patient survival. We then selected 
5 genes (DUSP6, MMD, STAT1, ERBB3 and LCK) and developed a 
risk predictive model based on RT-PCR and decision-tree approach. 
The 5-gene signature is an independent predictor of cancer recurrence 
and overall survival of NSCLC patients. We validated the model in an 
independent cohort of 60 NSCLC patients and also in an independent 
set of 86 western patients from published microarray data. This study 
can identify the patients with high risk gene signature in early stage. 
It may be a useful tool for risk prediction and designation of adjuvant 
treatment for high risk patients after validation in a prospective clini-
cal trial. To move a step forward, we identiﬁed a unique microRNA 
signature that can predict the survival and relapse of 112 NSCLC 
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patients. We re-conﬁrmed these ﬁndings in an independent cohort of 
56 NSCLC patients. The microRNA signature can distinguish high or 
low-risk patients with signiﬁcantly different survival within stage I, II, 
III, adenocarcinoma or squamous cell carcinoma subgroups of NSCLC 
patients. Our study supports the concept that cancer genomics has great 
potential for clinical application of personalized therapy. 
We also used microarray and lung cancer invasion/metastasis cell line 
model to identify novel biomarkers and treatment targets of lung can-
cer. We have identiﬁed two invasion/metastasis suppressors: CRMP-1 
and HLJ1. The microarray pathway analysis also helps to uncover 
their action mechanisms. The HLJ1-expression inhibited lung cancer 
cell proliferation, tumorigenesis, angiogenesis, cell motility, invasion 
and slowed cell cycle progression through a novel HLJ1/STAT1/ P21 
WAF1 pathway that is P53 and interferon independent. The HLJ1 is co-
regulated by YY1 at enhancer and AP1 at enhancer. HLJ1-expression 
is associated with reduced cancer recurrence and prolonged survival of 
NSCLC patients. These gene signatures and novel biomarkers can be 
used to predict clinical outcome and are potential treatment targets for 
lung cancer patients. 
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Platin doublets are the standard of care in ﬁrst line chemotherapy of 
advanced Non small cell lung cancer. The 1-year survival that can be 
achieved by chemotherapy is around 40 %.
During the past few years the major goal to improve the survival data 
was to include targeted therapies and drugs in the treatment strategy of 
NSCLC.
Stepwise success has been observed with several drugs like EGFR 
inhibitors. Nevertheless, new cytotoxics are under development as well 
to improve even efﬁcacy and optimize toxicity with increased QOL 
during the treatment course.
Novel taxanes:
Docetaxel/Paclitaxel are standards in 1st line combination and as single 
agents in 2nd line treatment for NSCLC. There are limitations for both 
drugs in efﬁcacy, tolerability and feasibility. Drug-conjugates might 
increase accumulation in tumors through enhanced permeation. Ad-
ditionally there is no need for toxic solubilizing agents.
During the last few years we have some new compounds
 Albumin bound Paclitaxel (Abraxane)
 Makromolecule drug conjugate (Xyotax)
 Oral Taxanes (BMS 275183,BAY 598862)
Xyotax was examined within 4 large phase III trials in 1st and 2nd line 
in NSCLC.
 Study design: Stellar 2 (2nd line): Xyotax vs Docetaxel
 Stellar 3 (1st line): Xyotax/Carbo vs Paclitaxel/Carbo
 Stellar 4 (PS2): Xyotax vs Gemcitabine or Vinorelbine
Pioneer : Xyotax vs Paclitaxel
The results so far available showed similar survival,TTP, DCR. In 
women there was a trend towards increased survival. Regarding toxic-
ity there was less myalgia and arthralgia,less alopecia,more nausea 
and vomiting,more grade Ê thrombocytopenia and delayed time to 
neuropathy.
Abraxane was found to have clinical advantages in comparison to Pa-
clitaxel in metastatic breast cancer. The phase I/II program in NSCLC 
is ﬁnished. The drug has activity in NSCLC as sinle agent and in com-
bination. A phase III program is under development.
The oral Taxanes are under investigation still in the phase I/II trials. 
Epothylones:
The rationally designed, fully synthetic epothilone ZK-EPO has 
demonstrated activity against non small cell lung cancer cell lines. The 
results of the ﬁrst completed Phase I study (one 30-min infusion q3w) 
demonstrated good tolerability, with peripheral neuropathy as the most 
common toxicity. Signs of activity, including a promising number of 
objective responses, were reported. A randomised Phase II trial was 
performed to determine the efﬁcacy and safety of ZK-EPO as second 
line therapy (one 3-hour infusion q3w) in patients with stage IIIB and 
IV non small cell lung cancer. 
A total of 44 patients have entered the study. A total of 113 infusions 
were administered to patients. 4 of the ﬁrst 38 evaluable patients did 
show response. The most common drug-related toxicity was peripheral 
sensory neuropathy (< grade 3 in 45% of patients, grade 3 in 14%). 
Seven patients discontinued treatment due to neuropathy. Other drug-
related toxicities (≥ 5%) were myalgia(23%), alopecia (18%), nausea 
(16%), fatigue (16%), vomiting (14%), constipation (9%), arthralgia 
(5%), fever (5%), dizziness (5%), diarrhea (5%), anorexia (5%).
Although the envisaged activity mark was not reached, this preliminary 
data indicate that ZK-EPO, administered as a 3-hour infusion at a dose 
of 16 mg/m2, has promising activity as second line treatment of non 
small cell lung cancer. Peripheral neuropathy currently appears to be 
the only noteworthy toxicity of ZK EPO. 
Pemetrexed:
Pemetrexed is approved in 2nd line treatment in NSCLC. There is 
reasonable activity and good safety proﬁle.
Nevertheless there are a lot of open questions 
activity in 1st line combinations
role of pemetrexed combinations in the adjuvant setting
combined modality treatment + radiotherapy in locally advanced inop-
erable NSCLC 
A lot of randomized trials are underway to answer these questions. 
Some results might be available at the conference.
Customized therapy:
Another aspect to improve chemotherapeutic results during the last 
few years was to develop Ïcustomized therapiesÓ based on pharma-
cogenomic data to select patients with NSCLC having the chance to 
optimize standard chemotherapy.
ERCC1 and RRM1 (DNA repair-enzymes) are such markers which 
have been tested within clinical trials to select patients with platinum- 
or gemcitabine resistance.
High ERCC1 level are correlated with poorer survival after platinum-
based chemotherapy.
Low RRM1 level seemed to be a sign for better gemcitabine-efﬁcacy.
These data must be conﬁrmed within large phase III trials in the future.
